Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care.
|Articles|March 17, 2010
Supplements and Featured Publications
- Issues in Improving the Treatment of Anemia: Negotiating the Shifting Regulatory and Clinical Landsc
- Volume 16
- Issue 3 Suppl
Posttest: Issues in Improving the Treatment of Anemia: Negotiating the Shifting Regulatory and Clinical Landscapes
Advertisement
Instructions
After reading “Issues in Improving the Treatment of Anemia: Negotiating the Shifting Regulatory and Clinical Landscapes,” complete the program evaluation and select the 1 best answer to each of the posttest questions.
A statement of continuing education hours will be provided to those physicians and pharmacists who successfully complete and return the answer form and program evaluation and receive a passing grade of 70% or higher.
Articles in this issue
Advertisement
Related to this article
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.
The regulatory decisions reflect how advances in biomarkers and molecular medicine are reshaping both diagnosis and treatment.
Measles cases hit a year high. Here's what payers need to know about outbreak costs, MMR coverage, and plans to split the vaccine
As peptides go mainstream, the FDA's shifting rules and a fractured state patchwork leave patients navigating a largely unregulated gray market.
Community oncologists cited prior authorization as a care barrier, even as AI adoption doubled in 2026, according to the Oncology Care Index.
A large propensity-matched study linked outpatient melatonin use to a small reduction in REM sleep in children evaluated for polysomnography.
Prior authorization and compounded drugs remain top obesity care access barriers, says NYU Langone's Holly Lofton, MD.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Part D Ruxolitinib Spending Hits $49.6 Million as Use Surges
2
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
3
Surrogate End Points, Drug Costs Complicate Oncology Formularies
4
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
5